AU2004293369A1 - Compositions and methods for the treatment of systemic lupus erythematosis - Google Patents

Compositions and methods for the treatment of systemic lupus erythematosis Download PDF

Info

Publication number
AU2004293369A1
AU2004293369A1 AU2004293369A AU2004293369A AU2004293369A1 AU 2004293369 A1 AU2004293369 A1 AU 2004293369A1 AU 2004293369 A AU2004293369 A AU 2004293369A AU 2004293369 A AU2004293369 A AU 2004293369A AU 2004293369 A1 AU2004293369 A1 AU 2004293369A1
Authority
AU
Australia
Prior art keywords
polypeptide
pro
antibody
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004293369A
Other languages
English (en)
Other versions
AU2004293369A2 (en
Inventor
Alexander Abbas
Sarah Bodary
Hilary Clark
Jill Schoenfeld
P. Mickey Williams
William I. Wood
Thomas D. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2004293369A2 publication Critical patent/AU2004293369A2/en
Publication of AU2004293369A1 publication Critical patent/AU2004293369A1/en
Priority to AU2011202082A priority Critical patent/AU2011202082A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
AU2004293369A 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis Abandoned AU2004293369A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011202082A AU2011202082A1 (en) 2003-03-03 2011-05-05 Compositions and methods for the treatment of systemic lupus erythematosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45188403P 2003-03-03 2003-03-03
US60/451,884 2003-03-03
PCT/US2004/006460 WO2005051988A2 (en) 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011202082A Division AU2011202082A1 (en) 2003-03-03 2011-05-05 Compositions and methods for the treatment of systemic lupus erythematosis

Publications (2)

Publication Number Publication Date
AU2004293369A2 AU2004293369A2 (en) 2005-06-09
AU2004293369A1 true AU2004293369A1 (en) 2005-06-09

Family

ID=34632721

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2004293369A Abandoned AU2004293369A1 (en) 2003-03-03 2004-03-02 Compositions and methods for the treatment of systemic lupus erythematosis
AU2011202082A Abandoned AU2011202082A1 (en) 2003-03-03 2011-05-05 Compositions and methods for the treatment of systemic lupus erythematosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2011202082A Abandoned AU2011202082A1 (en) 2003-03-03 2011-05-05 Compositions and methods for the treatment of systemic lupus erythematosis

Country Status (6)

Country Link
US (2) US7749695B2 (enExample)
EP (1) EP1599498A2 (enExample)
JP (3) JP2008500009A (enExample)
AU (2) AU2004293369A1 (enExample)
CA (1) CA2518101A1 (enExample)
WO (1) WO2005051988A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7790861B2 (en) * 1999-09-24 2010-09-07 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US7754435B2 (en) * 2000-09-21 2010-07-13 Philadelphia Health And Education Corporation Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
WO2007043103A1 (ja) * 2005-09-30 2007-04-19 Kansai Technology Licensing Organization Co., Ltd. シェーグレン症候群診断法及び診断キット
AU2007244868B2 (en) * 2006-04-24 2013-11-21 Genentech, Inc. Methods and compositions for detecting autoimmune disorders
US20100104581A1 (en) * 2006-05-25 2010-04-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions
EP1905841A1 (en) * 2006-09-25 2008-04-02 Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch; Trex1 as a marker for lupus erythematosus
WO2010011965A2 (en) * 2008-07-24 2010-01-28 The Regents Of The University Of California Identifying high risk clinically isolated syndrome patients
AU2010289383B2 (en) * 2009-09-03 2015-04-16 Medimmune, Llc Type 1 interferon diagnostic
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
JP6403663B2 (ja) 2012-03-28 2018-10-10 ガデタ・ベー・フェー コンビナトリアルガンマ９デルタ２ｔ細胞レセプター鎖交換
PL3469361T3 (pl) 2016-06-10 2025-02-03 Gadeta B.V. Nowy sposób identyfikacji łańcuchów receptora limfocytu t delta (lub limfocytu t gamma) lub części tych łańcuchów, które pośredniczą w odpowiedzi przeciwnowotworowej lub przeciwzakaźnej
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
KR20210013543A (ko) * 2018-01-09 2021-02-04 이매진 파마 내피 세포 기능장애를 조절하기 위한 rps2 펩타이드의 용도
GB202012804D0 (en) * 2020-08-17 2020-09-30 Univ London Queen Mary Agrin polypeptide and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016660A1 (en) * 1991-03-22 1992-10-01 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
IL141551A0 (en) * 1998-09-17 2002-03-10 Genentech Inc Compositions and methods for the treatment of immune related diseases
CA2362427A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2365223A1 (en) * 1999-03-19 2000-09-28 Craig A. Rosen 46 human secreted proteins
JP4211966B2 (ja) * 1999-11-30 2009-01-21 ジェネンテック・インコーポレーテッド 免疫関連疾患を治療するための組成物及び方法
CA2391374A1 (en) * 1999-12-23 2001-06-28 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
CA2399776A1 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020081597A1 (en) 2000-03-31 2002-06-27 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
JP2004528810A (ja) * 2000-10-02 2004-09-24 バイエル コーポレーション 癌組織でディファレンシャルに発現される核酸配列
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
EP1409677A2 (en) 2001-01-19 2004-04-21 Incyte Genomics, Inc. Receptors and membrane-associated proteins
WO2003010327A2 (en) * 2001-02-21 2003-02-06 Curagen Corporation Novel proteins and nucleic acids encoding same
EP1478772A2 (en) * 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
US6489153B1 (en) * 2001-10-31 2002-12-03 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20040258678A1 (en) * 2002-02-22 2004-12-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US7118865B2 (en) * 2002-08-16 2006-10-10 Regents Of The University Of Minnesota Methods for diagnosing severe systemic lupus erythematosus
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) * 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
CA2500687A1 (en) * 2002-10-02 2004-04-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2004043397A2 (en) * 2002-11-12 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of rheumatoid arthritis
JP2011516026A (ja) * 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus

Also Published As

Publication number Publication date
JP2010207229A (ja) 2010-09-24
US20090054300A1 (en) 2009-02-26
EP1599498A2 (en) 2005-11-30
AU2004293369A2 (en) 2005-06-09
JP2013240329A (ja) 2013-12-05
AU2011202082A1 (en) 2011-05-26
CA2518101A1 (en) 2005-06-09
US7749695B2 (en) 2010-07-06
US20110142841A1 (en) 2011-06-16
WO2005051988A3 (en) 2005-07-28
JP2008500009A (ja) 2008-01-10
WO2005051988A2 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
AU2003291625B2 (en) Compositions and methods for the treatment of immune related diseases
AU2003295401B2 (en) Compositions and methods for the treatment of natural killer cell related diseases
AU2010203031B2 (en) Novel compositions and methods for the treatment of psoriasis
US20110142841A1 (en) Compositions and methods for the treatment of systemic lupus erythematosis
AU2003284357A1 (en) Compositions and methods for the treatment of immune related diseases
AU2009243454A1 (en) Novel composition and methods for the treatment of psoriasis
AU2004219603A1 (en) Novel compositions and methods for the treatment of immune related disease
AU2010200528B2 (en) Compositions and methods for the treatment of immune related diseases
US20140018250A1 (en) Compositions and methods for the treatment of immune related diseases
US20090186018A1 (en) Compositions and methods for the treatment of rheumatoid arthritis
AU2003263045A1 (en) Novel compositions and methods for the treatment of psoriasis
AU2003267070A1 (en) Novel compositions and methods for the treatment of immune-related diseases

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 SEP 2006

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted